1
Home
Companies

Liquidia Technologies

#5578

Rank

$1.12B

Marketcap

US United States

Country

Liquidia Technologies
Leadership team

Dr. Roger A. Jeffs Ph.D. (CEO & Director)

Mr. Robert A. Lippe (Chief Operations Officer)

Dr. Tushar Shah M.D. (Sr. VP of Product Devel.)

Products/ Services
Biopharma, Biotechnology, Nanotechnology, Therapeutics
Number of Employees
50 - 100
Headquarters
Morrisville, North Carolina, United States
Established
2004
Company Registration
SEC CIK number: 0001819576
Revenue
5M - 20M
Traded as
LQDA
Social Media
URL
https://www.liquidia.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
History

Liquidia Technologies is an innovative biopharmaceutical company that is focused on transforming the lives of patients by engineering precision medicines using its PRINT® technology platform. Founded in 2004, the company has been advancing its pipeline of drug candidates designed to treat chronic and life-threatening conditions. Liquidia’s PRINT® platform uses proprietary particle engineering technology to engineer precision dose forms of existing therapies.

Mission
Liquidia’s mission is to develop and deliver meaningful clinical therapies that can improve the lives of patients by leveraging the power of advanced engineering to precisely engineer medicine.
Vision
To realize our mission, Liquidia strives to be a leader in precision medicine to create meaningful medical solutions to the world’s greatest unmet medical needs.
Key Team

Mr. William R. Kenan Jr. (Co-Founder)

Dr. Ginger Denison (Co-Founder)

Mr. Michael Kaseta (Chief Financial Officer)

Jennifer Almond (Director of Investor Relations & Corp. Communications)

Mr. Jason Adair (Sr. VP of Corp. Devel. & Strategy)

Mr. Russell Schundler (Gen. Counsel & Corp. Sec.)

Ms. Celia Reyes-Hoke (VP of People & Culture)

Recognition and Awards
Liquidia has earned a range of awards since its founding in 2004, ranging from the International Forum for Fab Lab Innovation Award to recognition from the US National Institutes of Health and US National Science Foundation for its advanced engineering research. The company was also named to the 2019 FierceBioTech Fierce 15 List of groundbreaking biotech companies.
References

https://in.investing.com/equities/liquidia-technologies-inc

https://finance.yahoo.com/quote/LQDA/profile?p=LQDA

https://www.crunchbase.com/organization/liquidia-technologies

https://companiesmarketcap.com/

https://www.liquidia.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Liquidia Technologies
Leadership team

Dr. Roger A. Jeffs Ph.D. (CEO & Director)

Mr. Robert A. Lippe (Chief Operations Officer)

Dr. Tushar Shah M.D. (Sr. VP of Product Devel.)

Products/ Services
Biopharma, Biotechnology, Nanotechnology, Therapeutics
Number of Employees
50 - 100
Headquarters
Morrisville, North Carolina, United States
Established
2004
Company Registration
SEC CIK number: 0001819576
Revenue
5M - 20M
Traded as
LQDA
Social Media
URL
https://www.liquidia.com